PFE-360

TargetMol
Product Code: TAR-T16512
Supplier: TargetMol
CodeSizePrice
TAR-T16512-1mg1mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-2mg2mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-5mg5mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-1mL1 mL * 10 mM (in DMSO)£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-10mg10mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-25mg25mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-50mg50mg£646.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16512-500mg500mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
PFE-360 is a potent and selective inhibitor of LRRK2 kinase (IC50: 2.3 nM in vivo).
CAS:
1527475-61-1
Formula:
C16H16N6O
Molecular Weight:
308.345
Pathway:
Autophagy
Purity:
0.9991
SMILES:
Cn1cc(cc1C#N)-c1c[nH]c2ncnc(N3CCOCC3)c12
Target:
LRRK2

References

1. Marco A.S. Baptista, et al. LRRK2 Kinase Inhibitors of Different Structural Classes Induce Abnormal Accumulation of Lamellar Bodies in Type II Pneumocytes in Non-Human Primates but are Reversible and Without Pulmonary Functional Consequences. 2. Andersen MA, et al. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-?-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27. 3. Andersen MA, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22.